Prosecution Insights
Last updated: April 19, 2026
Application No. 17/795,081

BIOPHARMACEUTICAL MANUFACTURING PROCESS AND PRODUCT

Final Rejection §103§112
Filed
Jul 25, 2022
Examiner
MAYY, MOHAMMAD
Art Unit
1718
Tech Center
1700 — Chemical & Materials Engineering
Assignee
Silcotek Corp.
OA Round
4 (Final)
48%
Grant Probability
Moderate
5-6
OA Rounds
3y 3m
To Grant
71%
With Interview

Examiner Intelligence

Grants 48% of resolved cases
48%
Career Allow Rate
194 granted / 408 resolved
-17.5% vs TC avg
Strong +23% interview lift
Without
With
+23.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 3m
Avg Prosecution
32 currently pending
Career history
440
Total Applications
across all art units

Statute-Specific Performance

§101
0.6%
-39.4% vs TC avg
§103
58.6%
+18.6% vs TC avg
§102
10.5%
-29.5% vs TC avg
§112
23.0%
-17.0% vs TC avg
Black line = Tech Center average estimate • Based on career data from 408 resolved cases

Office Action

§103 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Claims 3, 6, 16 cancelled Claims 1, 20-21 and 23 amended Claims 1-2, 4-5, 7-15, 17-23 pending Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 2, 4-5, 7-8 and 22-23 rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 2, 4-5, 7-8 states “the liquid”, where those claims depends on claim 1, and claim 1 state “first liquid” and “second liquid”. Therefore, it is not clear which “liquid” those claims refers to. Claims 22-23 states “the liquid”, where those claims depends on claim 21, and claim 21 state “first liquid” and “second liquid”. Therefore, it is not clear which “liquid” those claims refers to. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. Claim(s) 1-2, 4-5, 7-13, 17-23 are rejected under 35 U.S.C. 103 as being unpatentable over Bischof (PG Pub 2019/0262745) in view of Sah (EP 2246362), and in further view of Thoen (PG Pub 2014/0342399 A1). Consider Claims 1-2, 4-5, 7-9, 17-23, Bischof discloses a pharmaceutical manufacturing process [0008] comprising flowing a liquid through a pathway [0016] wherein the liquid contacts a non-polymeric coating on a substrate within the pathway [0039], wherein the substrate is metallic [0017]. The liquid includes active pharmaceutical ingredients, water for injection [0016] (Fig. 1), an acid, or phosphoric acid [0040]. The liquid may include nitric acid [0014]. The substrate is susceptible to corrosion from the liquid wherein the non-polymeric coating does not corrode [0040]. The substrate is stainless steel [0020], and the non-polymeric coating includes silicon, oxygen, carbon, and/or nitrogen [0039]. Bischof does not disclose that the liquid includes guanidine hydrochloride. Sah discloses proteins solubilized in a liquid, such as guanidine hydrochloride, which flow through a pathway of a chromatography column [0226]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the present invention to flow the liquid of Sah through a column coated with the non-polymeric coating of Bischof since the non-polymeric coating protects against HCl [0004]. The combine Bischof (with Sah) does not teach the cleaning with a second liquid by flowing though the pathway. However, Thoen is in the prior art of processing analyte using HPLC [0120], teaches the step of rinsing the column clean after each run (testing the analyte) [0125]. A person having ordinary skill in the art before the effective date of the claimed invention would combine Bischof (with Sah) with Thoen to flow a second liquid to rinse and clean the pathway (of the column) with a second cleaning solution, to remove a new test sample contamination from previous test samples, as to prevent cross contamination from previous run. Consider Claims 10-13 and 20, the combined Bischof (with Sah and Thoen) does not explicitly disclose the pathway includes a weld, a corner, a flange, or threaded portions. However, Bischof discloses other components of the system which come in contact with the fluid can similarly be coated, such as fittings, valves, tubings, etc. [0016]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the present invention to coat any portion of the pathway, including components such as a weld, corner, etc. of Bischof since additional components of the system can be coated. Claim(s) 14-15 are rejected under 35 U.S.C. 103 as being unpatentable over Bischof (PG Pub 2019/0262745) in view of Sah (EP 2246362), and in further view of Thoen (PG Pub 2014/0342399 A1) and in further view of Carr (PG Pub 2015/0122365). Consider Claims 21-23, Bischof does not disclose the surface roughness of the substrate. Carr discloses coating an interior surface of a metallic pathway with a protective coating [0052]; [0060]-[0061] since metal structures, such as tubing, may have a significant amount of surface roughness [0052]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the present invention that the protective coatings of Bischof and Carr to be applied to substrates having surface roughness within the claimed ranges because the coatings are suitable for protecting metallic substrates with significant amount of surface roughness. Response to Arguments Applicant’s arguments, filed 12/29/2025, with respect to the rejection(s) of claim(s) 1-2, 4-5, 7-15, 17-23 under 102/103a have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Bischof with Sah and Thoen. The applicant argued based on the newly amended claims, on the ground that Bischof with Sah does not disclose the use of a second liquid of cleaning solution though the pathway. However, the newly applied prior art of Thoen discloses the process of running the HPLC with samples (first liquid) through the column/pathway, then cleaning using cleaning solution with a second liquid [0125] through the column/pathway, to prevent cross contamination between samples. All other applicant arguments not specifically addressed above are deemed unpersuasive as either not commensurate in scope with the broadly drafted claims or are unsupported by factual evidence and are deemed mere attorney speculation. Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Mohammad Mayy whose telephone number is (571)272-9983. The examiner can normally be reached Monday to Friday, 11:00AM-7:00PM EST. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gordon Baldwin can be reached at 571-272-5166. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /Mohammad Mayy/ Art Unit 1718 /GORDON BALDWIN/Supervisory Patent Examiner, Art Unit 1718
Read full office action

Prosecution Timeline

Jul 25, 2022
Application Filed
Jun 15, 2024
Non-Final Rejection — §103, §112
Jun 25, 2024
Response Filed
Oct 15, 2024
Final Rejection — §103, §112
Mar 18, 2025
Response after Non-Final Action
Apr 17, 2025
Request for Continued Examination
Apr 17, 2025
Response after Non-Final Action
May 12, 2025
Response after Non-Final Action
Sep 04, 2025
Non-Final Rejection — §103, §112
Dec 10, 2025
Response after Non-Final Action
Dec 10, 2025
Response Filed
Dec 29, 2025
Response Filed
Jan 29, 2026
Final Rejection — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12603199
METHOD FOR IMPROVING ANTI-REDUCTION PERFORMANCE OF PTC THERMOSENSITIVE ELEMENT
2y 5m to grant Granted Apr 14, 2026
Patent 12595551
METHOD FOR THE SURFACE TREATMENT OF PARTICLES OF A METAL POWDER AND METAL POWDER PARTICLES OBTAINED THEREBY
2y 5m to grant Granted Apr 07, 2026
Patent 12577732
METHOD OF MAKING FIRE RETARDANT MATERIALS AND RELATED PRODUCTS
2y 5m to grant Granted Mar 17, 2026
Patent 12546010
Turbine Engine Shaft Coating
2y 5m to grant Granted Feb 10, 2026
Patent 12546001
COMPOSITION FOR DEPOSITING A SILICON-CONTAINING LAYER AND METHOD OF DEPOSITING A SILICON-CONTAINING LAYER USING THE SAME
2y 5m to grant Granted Feb 10, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

5-6
Expected OA Rounds
48%
Grant Probability
71%
With Interview (+23.3%)
3y 3m
Median Time to Grant
High
PTA Risk
Based on 408 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month